Table 4.
Phenotype of negatively isolated rheumatoid arthritis (RA)-synovial fibroblasts (SFB) in comparison with osteoarthritis (OA)-SFB and normal skin-FB
| skin-FB (n = 8) | OA-SFB (n = 9) | RA-SFB (n = 9) | ||||
| Antigen | Percent | MFI | Percent | MFI | Percent | MFI |
| Thy-1 (CD90; mAb AS02) | 91.4 ± 3.0 | 156 ± 36 | 62.1 ± 9.0# | 120 ± 36 | 73.8 ± 9.6 | 109 ± 20 |
| MHC-I | 90.2 ± 8.5 | 414 ± 119 | c87.7 ± 6.8 | 759 ± 170 | a77.2 ± 8.1 | 130 ± 54x |
| MHC-II | 1.5 ± 0.4 | 225 ± 67 | c17.0 ± 7.3# | 678 ± 137# | a65.8 ± 12.3#x | 223 ± 84x |
| Aminopeptidase N (CD13) | b84.0 ± 10.2 | 365 ± 163 | a83.2 ± 8.7 | 794 ± 207 | 84.8 ± 5.9 | 444 ± 226 |
| VCAM-1 (CD 106) | c8.3 ± 3.4 | 66 ± 33 | a28.9 ± 13.2 | 156 ± 82 | c17.5 ± 9.8 | 122 ± 42 |
| Prolyl-4-hydroxylase | 70.7 ± 15.2 | 101 ± 31 | a92.2 ± 2.8 | 212 ± 44 | 84.8 ± 2.9 | 164 ± 45 |
| Vimentin | a90.3 ± 4.2 | 133 ± 34 | b94.2 ± 1.7 | 1083 ± 530 | a93.2 ± 1.5 | 592 ± 290 |
| Procollagen I | d68.2 ± 8.3 | 18 ± 1 | d27.5 ± 10.4 | 39 ± 5# | a44.8 ± 13.0 | 25 ± 2x |
| Procollagen III | d55.1 ± 9.8 | 15 ± 2 | d22.1 ± 7.8 | 45 ± 9# | a50.0 ± 14.3 | 26 ± 3# |
| c-Fos | d87.2 ± 2.1 | 17 ± 3 | d53.9 ± 10.4 | 35 ± 2# | a57.4 ± 14.0 | 20 ± 2x |
| c-Jun | d42.7 ± 15.6 | 13 ± 3 | d22.2 ± 10.3 | 29 ± 3 | b42.5 ± 14.0 | 21 ± 5 |
| Jun-D | d87.4 ± 1.5 | 19 ± 5 | d37.6 ± 17.7 | 33 ± 1# | a53.0 ± 14.8 | 21 ± 4 |
Data presented as means ± SEM. MFI, Mean fluorescence intensity; mAb, monoclonal antibody; MHC, major histocompatibility complex; VCAM-1, vascular adhesion molecule-1. Significant differences among groups are indicated in bold. All cell populations were isolated/obtained from primary culture (in the case of skin-FB from primary culture or first passage; see Methods for details). #P ≤ 0.05 Mann-Whitney U test versus skin-FB. xP ≤ 0.05 Mann-Whitney U test versus OA-SFB. an = 7 Normals, OA or RA patients. bn = 6 Normals, OA or RA patients. cn = 5 Normals, OA or RA patients. dn = 3 Normals or OA patients.